Craig Devoe, MD
Hematology & Oncology · Lake Success, NYNPI 1407927593
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,150 of the $3,364 with a category attached, or 93.6%. Array Biopharma Inc accounts for 93.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $2,520 and has fallen 97.9% since, to $53 in 2025.
Across 5 payments — averaging $672.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Array Biopharma Inc$3K
- Intera Oncology, Inc$141
- Genentech, Inc.$53
- Varian Medical Systems, Inc.$20
Across 47 payments — averaging $9313.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$86K
- Merck$80K
- Halozyme Inc$65K
- EMD Serono, Inc.$61K
- Regeneron$61K
- Immunocore Limited$59K
- plus $26K from 2 others
What the payments were for
- Speaking & faculty fees$3,15094%
- Food & beverage$1615%
- Education$532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Array Biopharma Inc | 2 | $3,150 |
| Intera Oncology, Inc | 1 | $141 |
| Genentech, Inc. | 1 | $53 |
| Varian Medical Systems, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MEKTOVI$2,520
- BRAFTOVI$630
- Intera 3000 Implantable Pump$141
How this compares
$3,364 in reported general payments places this provider in the 60th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 30 | $317,558 |
| GleevecImatinib Mesylate | 14 | $203,568 |
| Imatinib Mesylate | 17 | $28,595 |
| CreonLipase/Protease/Amylase | 11 | $24,704 |
| EliquisApixaban | 16 | $9,309 |
| Ondansetron OdtOndansetron | 33 | $313 |
| Dexamethasone | 22 | $286 |
| Prednisone | 35 | $286 |
| Pantoprazole Sodium | 11 | $101 |
| Famotidine | 12 | $81 |
| Ciprofloxacin Hcl | 12 | $55 |
| Furosemide | 26 | $55 |
| Metoclopramide Hcl | 15 | $32 |
| Spironolactone | 14 | $24 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lake Success
- Francis ArenaLake Success$1M
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.